联合 PARP-1 和 VEGF 抑制在严重 SARS-CoV-2（COVID-19）感染中的潜在作用。
The potential role of the combined PARP-1 and VEGF inhibition in severe SARS-CoV-2 (COVID-19) infection.
机构信息
Second Department of Medical Oncology, General Oncology Hospital of Kifissia "Agioi Anargiroi", Athens, Nea Kifissia, Greece.
Department of Anatomy and Surgical Anatomy, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
出版信息
J Infect Dev Ctries. 2022 Jan 31;16(1):101-111. doi: 10.3855/jidc.15386.
INTRODUCTION
During the evolution of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several drug candidates have been proposed for repositioning towards a quest for more effective treatments.
METHODOLOGY
We reviewed recent literature (Pubmed, Google, Clinicaltrials.gov), as of the middle of May 2021, for evidence regarding the potential benefit from poly(ADP-ribose)-polymerase inhibitors and vascular endothelial growth factor blockade in severe SARS-CoV-2 infection.
RESULTS
poly(ADP-ribose)-polymerase inhibitors have been suggested as potential agents against coronavirus disease 2019 (COVID-19) by a variety of mechanisms. vascular endothelial growth factor-associated vascular permeability is implicated with increased vascular leakage and pulmonary oedema. Thus, anti-angiogenesis factors, such as bevacizumab are being investigated in critically ill COVID-19 patients.
CONCLUSIONS
The synergistic potential of these two classes of inhibitors in severe COVID-19 management could be beneficial. Further research should be carried out in order to support this hypothesis.
简介
在新型严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）大流行的演变过程中，已经提出了几种候选药物，以便重新定位以寻求更有效的治疗方法。
方法
截至 2021 年 5 月中旬，我们回顾了最近的文献（PubMed、Google、Clinicaltrials.gov），以获取有关多聚（ADP-核糖）聚合酶抑制剂和血管内皮生长因子阻断在严重 SARS-CoV-2 感染中的潜在益处的证据。
结果
多聚（ADP-核糖）聚合酶抑制剂通过多种机制被认为是对抗 2019 年冠状病毒病（COVID-19）的潜在药物。血管内皮生长因子相关的血管通透性与血管渗漏和肺水肿增加有关。因此，贝伐珠单抗等抗血管生成因子正在重症 COVID-19 患者中进行研究。
结论
这两类抑制剂在严重 COVID-19 管理中的协同潜力可能是有益的。应该进行进一步的研究来支持这一假设。
Zotero 插件